{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:10:25Z","timestamp":1792746625026,"version":"4.5.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016945","name":"Sidney Kimmel Center for Prostate and Urologic Cancers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50-CA92629"],"award-info":[{"award-number":["P50-CA92629"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euo.2025.12.013","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T12:15:24Z","timestamp":1767183324000},"page":"524-528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of Results from the BARCODE1 Study and Contemporary Prostate Cancer Screening Trials"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6133-0164","authenticated-orcid":false,"given":"Amit","family":"Sud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"McNeill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.12.013_b0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071082","article-title":"Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit","volume":"381","author":"Vickers","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2025.12.013_b0010","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa2407934","article-title":"Assessment of a polygenic risk score in screening for prostate cancer","volume":"392","author":"McHugh","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.12.013_b0015","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa2406050","article-title":"Results after four years of screening for prostate cancer with PSA and MRI","volume":"391","author":"Hugosson","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.12.013_b0020","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2024.3841","article-title":"Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial","volume":"331","author":"Auvinen","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2025.12.013_b0025","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/s41436-018-0418-5","article-title":"The illusion of polygenic disease risk prediction","volume":"21","author":"Wald","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.euo.2025.12.013_b0030","article-title":"Evaluating the utility of polygenic risk scores in identifying high-risk individuals for eight common cancers","volume":"4","author":"Jia","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.euo.2025.12.013_b0035","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2023-000554","article-title":"Performance of polygenic risk scores in screening, prediction, and risk stratification: secondary analysis of data in the Polygenic Score Catalog","volume":"2","author":"Hingorani","year":"2023","journal-title":"BMJ Med"},{"key":"10.1016\/j.euo.2025.12.013_b0040","doi-asserted-by":"crossref","first-page":"171","DOI":"10.7326\/M13-1484","article-title":"Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis","volume":"160","author":"Lee","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euo.2025.12.013_b0045","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa052911","article-title":"Diagnostic performance of digital versus film mammography for breast-cancer screening","volume":"353","author":"Pisano","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.12.013_b0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g2296","article-title":"Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study","volume":"348","author":"Carlsson","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2025.12.013_b0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41698-022-00280-w","article-title":"Polygenic risk scores to stratify cancer screening should predict mortality not incidence","volume":"6","author":"Vickers","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.euo.2025.12.013_b0060","doi-asserted-by":"crossref","unstructured":"Dixon P, Aning J, Martin RM, Clements M. Modelling the potential contributions of polygenic risk stratification to cost-effective screening for prostate cancer. medRxiv. https:\/\/doi.org\/10.1101\/2025.05.19.25327897.","DOI":"10.1101\/2025.05.19.25327897"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125003396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125003396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T20:08:56Z","timestamp":1785010136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125003396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2588931125003396"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.12.013","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Results from the BARCODE1 Study and Contemporary Prostate Cancer Screening Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}